Fesnak and colleagues explore the issues surrounding the development of technologies for engineered T cell immunotherapy of B cell leukemia and lymphoma. Fesnak AD et al. Curr Hematol Malig Rep 2017; 12: 335-343. doi:10.1007/s11899-017-0395-9

Using a case-based approach, this chapter reviews the clinical characteristics of pediatric diffuse large B-cell lymphoma. Servitzoglou  MK et al. In:  PET/CT in lymphomas: a case-based atlas . Edited by Andreou JA et al. Springer International Publishing 2016. doi:10.1007/978-3-319-27380-8_21

Kim D-W et al. J Clin Oncol 2017; 35(22): 2490-2498. doi:10.1200/JCO.2016.71.5904

Ribi K, Rondeau S, Hitz F et al. Support Care Cancer 2017. doi:10.1007/s00520-017-3698-4

In this chapter, Manier et al. describe the 'driver' gene alterations involved in the development and progression of multiple myeloma (MM) and discuss the therapeutic implications of a comprehensive understanding of the genomic complexity of MM. Summary points The pathologic diagnosis of multiple myeloma (MM) and other plasma cell proliferative disorders (PCPD) is made on the bone marrow aspirate and biopsy specimen. The goal of the pathologic examination of the bone marrow is to: (a) quantify bone marrow plasma cells (PC); (b) establish PC clonality; (c) distinguish MM from lymphoplasmacytic lymphoma (LPL) and other B-cell lymphomas with plasmacytic differentiation; (d) analyze prognostic factors; (e) detect amyloid deposits; and (f) detect other potential pathologic processes. The standard of care for PC quantification is still morphologic assessment of the bone marrow aspirate and biopsy. Clonality of PCs is inferred by showing of monotypic immunoglobulin light chain expression (kappa or lambda) and/or abnormal patterns of antigen expression. Bone marrow examination helps differentiate LPL from MM. In MM, a monomorphic PC population is usually pure without associated lymphoid component, whereas in LPL small lymphocytes and plasmacytoid lymphocytes typically predominate. The most important laboratory prognostic factors are proliferation rate of neoplastic plasma cells and cytogenetic findings. Amyloid accumulation in extracellular space leads to multiple organ dysfunction; amyloid deposits can be detected in the tissue biopsy using Congo Red stain under polarized light. There is a wide range of pathologic processes that can accompany PCPDs. The most common ones are large granular lymphocyte proliferations and therapy-related myeloid neoplasms. Jevremovic D & Morice W. In: Multiple Myeloma . Edited by Gertz MA & Rajkumar SV. Springer New York, 2014. doi:10.1007/978-1-4614-8520-9_3

This review by Grover et al. discusses novel immunotherapeutic approaches to treat Hodgkin lymphoma, specifically programmed cell death-1 (PD-1) inhibitors and cellular immunotherapy. Grover NS, Savoldo B. Curr Hematol Malig Rep 2017. doi:10.1007/s11899-017-0398-6